Drug Profile
ICT 107
Alternative Names: Cancer vaccine - ImmunoCellular Therapeutics; Dendritic cell vaccines - ImmunoCellular Therapeutics; ICT-107Latest Information Update: 03 Sep 2021
Price :
$50
*
At a glance
- Originator ImmunoCellular Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Glioblastoma
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 03 Sep 2021 Discontinued - Phase-III for Glioblastoma (Combination therapy, First-line therapy) in USA, Austria, Canada, Netherlands, Germany, Spain (Intradermal) (ImmunoCellular Therapeutics website, September 2021)
- 08 May 2019 ImmunoCellular Therapeutics and Unknown company entered into a asset purchase agreement for ICT 107, ICT 140, ICT 121 and stem-to-T-cell research programme preclinical asset
- 21 Jun 2017 ICT 107 is available for licensing as of 21 Jun 2017. www.imuc.com